[go: up one dir, main page]

WO2008024139B1 - Inhibitors of fatty acid amide hydrolase - Google Patents

Inhibitors of fatty acid amide hydrolase

Info

Publication number
WO2008024139B1
WO2008024139B1 PCT/US2007/009434 US2007009434W WO2008024139B1 WO 2008024139 B1 WO2008024139 B1 WO 2008024139B1 US 2007009434 W US2007009434 W US 2007009434W WO 2008024139 B1 WO2008024139 B1 WO 2008024139B1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
diseases
disorder
disorders
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/009434
Other languages
French (fr)
Other versions
WO2008024139A2 (en
WO2008024139A3 (en
Inventor
David Putman
Jeff Parrott
Timothy R Compton
Olivier Dasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/561,774 external-priority patent/US20070155707A1/en
Priority claimed from PCT/US2006/049485 external-priority patent/WO2007079180A2/en
Application filed by Organon NV filed Critical Organon NV
Publication of WO2008024139A2 publication Critical patent/WO2008024139A2/en
Publication of WO2008024139A3 publication Critical patent/WO2008024139A3/en
Publication of WO2008024139B1 publication Critical patent/WO2008024139B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.

Claims

93AMENDED CLAIMS received by the International Bureau on 07 October 2008 (07.10.08)
1. 2-(4~((cyclohexylmethyl)carbamoyl)phenyl)acetic acid or a pharmaceutically acceptable salt thereof.
2. 3-acetamidophenylcyclohexylmethylcarbamate.or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising the compound according to claim 1.
4. A pharmaceutical composition comprising the compound according to claim 2.
5. A method of treating a disease, disorder or condition responsive to inhibition of fatty acid hydrolase activity in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1.
6. The method according to claim 5, wherein the disease, disorder or condition is selected from the group consisting of acute or chronic pain, eating disorders, cardiovascular diseases, metabolic diseases, disorders or conditions, renal ischemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory disease, osteoporosis, ocular conditions, pulmonary conditions, gastrointestinal diseases, and urinary incontinence.
7. The method according to claim 6, wherein the disease, disorder or condition is acute or chronic pain.
8. A method of treating a disease, disorder or condition responsive to inhibition of fatty acid hydrolase activity in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 2. 94
9. The method according to claim 8, wherein the disease, disorder or condition is selected from the group consisting of acute or chronic pain, eating disorders, cardiovascular diseases, metabolic diseases, disorders or conditions, renal ischemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory disease, osteoporosis, ocular conditions, pulmonary conditions, gastrointestinal diseases, and urinary incontinence.
10. The method according to claim 9, wherein the disease, disorder or condition is acute or chronic pain.
PCT/US2007/009434 2006-08-18 2007-04-17 Inhibitors of fatty acid amide hydrolase Ceased WO2008024139A2 (en)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US82287706P 2006-08-18 2006-08-18
US60/822,877 2006-08-18
US82307606P 2006-08-21 2006-08-21
US60/823,076 2006-08-21
US82488706P 2006-09-07 2006-09-07
US60/824,887 2006-09-07
US82786106P 2006-10-02 2006-10-02
US60/827,861 2006-10-02
US82875306P 2006-10-09 2006-10-09
US60/828,753 2006-10-09
US86656806P 2006-11-20 2006-11-20
US11/561,774 US20070155707A1 (en) 2005-12-29 2006-11-20 Ionizable inhibitors of fatty acid amide hydrolase
US60/866,568 2006-11-20
US11/561,774 2006-11-20
PCT/US2006/049485 WO2007079180A2 (en) 2005-12-29 2006-12-28 Inhibitors of fatty acid amide hydrolase
USPCT/US2020/06/049 2006-12-28

Publications (3)

Publication Number Publication Date
WO2008024139A2 WO2008024139A2 (en) 2008-02-28
WO2008024139A3 WO2008024139A3 (en) 2008-10-02
WO2008024139B1 true WO2008024139B1 (en) 2008-12-04

Family

ID=39110473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009434 Ceased WO2008024139A2 (en) 2006-08-18 2007-04-17 Inhibitors of fatty acid amide hydrolase

Country Status (1)

Country Link
WO (1) WO2008024139A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044052B2 (en) 2006-10-18 2011-10-25 Pfizer Inc. Biaryl ether urea compounds

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639621T3 (en) 2004-12-30 2017-10-27 Janssen Pharmaceutica N.V. Phenylamide derivatives of 4- (benzyl) -piperazine-1-carboxylic acid and related compounds as modulators of fatty acid amide hydrolase (FAAH) for the treatment of anxiety, pain and other conditions
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
WO2010068453A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
WO2013180698A1 (en) * 2012-05-30 2013-12-05 Alcon Research, Ltd. Use of faah antagonists for treating dry eye and ocular pain
US11096909B2 (en) 2016-04-06 2021-08-24 University Of Oulu Compounds for use in the treatment of cancer
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2018205275B2 (en) 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
KR20220007845A (en) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. Compounds and uses thereof
CN110354110B (en) * 2019-06-11 2021-03-12 江南大学 Lipase inhibitor and application thereof
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS
CN116332818B (en) * 2021-12-22 2023-12-15 王喆明 Tetrahydropyrrole derivatives and their applications
WO2025015420A1 (en) 2023-07-17 2025-01-23 Apogee Pharmaceuticals, Inc. Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040068240A (en) * 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US20080089845A1 (en) * 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044052B2 (en) 2006-10-18 2011-10-25 Pfizer Inc. Biaryl ether urea compounds

Also Published As

Publication number Publication date
WO2008024139A2 (en) 2008-02-28
WO2008024139A3 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2008024139B1 (en) Inhibitors of fatty acid amide hydrolase
US11524930B2 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
AU2020203101B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US8211922B2 (en) 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US9757348B2 (en) Composition and methods for treating intestinal hyperpermeability
WO2008063300A8 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
NZ599136A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
US20150164930A1 (en) Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
WO2008064136A3 (en) Compounds with activity at retinoic acid receptors
WO2011085033A3 (en) Dp2 antagonist and uses thereof
WO2007146126A3 (en) Insulin composition
WO2008153318A3 (en) Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof
JP7414712B2 (en) Compositions and methods for reducing serum cholesterol and PCSK9
CA2477720A1 (en) Quinoline derivatives
CN112469406B (en) Use of stearic acid for preventing or treating pulmonary fibrosis
EP0720849B1 (en) Agents for prevention or treatment of chronic rheumatism and sepsis
US7115660B2 (en) Methods for inhibiting angiogenesis and tumor growth
CN117547537B (en) Application of FN-1501 and its pharmaceutical composition
JPWO2020099926A5 (en)
WO2000051640A1 (en) Itchiness-relieving agents and itchiness-relieving effect potentiators
TWI461215B (en) Method and improved pharmaceutical composition for improving the absorption of an ester prodrug
WO2008015763A1 (en) Drug formulation containing fibrate medicament and process for producing the same
HK1143072A1 (en) Enhanced bioavailability of octreotide vis the gi tract using a suspension in a hydrophobic medium
JP2007008923A (en) Formulation containing fibrate and method for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755635

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07755635

Country of ref document: EP

Kind code of ref document: A2